Hologic to Go Private in $79/Share Deal with Blackstone, TPG

TL;DR

**SELL HOLX, the private equity buyout caps your upside, take the cash and CVR now.**

AI Summary

Hologic, Inc. (HOLX) reported a definitive agreement on October 21, 2025, to be acquired by funds managed by Blackstone Inc. and TPG Capital for $76.00 per share in cash, plus a non-tradable contingent value right (CVR) of up to $3.00 per share, totaling a potential $79.00 per share. The company operates in four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. Key products include molecular diagnostic assays like Aptima and Panther systems, 3D digital mammography systems, MyoSure and NovaSure surgical systems, and Horizon DXA for bone density. The Skeletal Health segment will discontinue sales of Fluoroscan Insight FD systems in fiscal 2026. The aggregate market value of Hologic's common stock held by non-affiliates was $13,566,017,923 as of March 29, 2025, with 222,905,228 shares outstanding as of November 13, 2025. This acquisition represents a significant strategic shift for Hologic, moving it from a publicly traded entity to private ownership under two major private equity firms.

Why It Matters

This acquisition by Blackstone and TPG Capital for up to $79.00 per share marks a pivotal moment for Hologic, transitioning it from a public company to private ownership. For investors, this offers a clear exit at a premium, but removes future public market upside. Employees may face organizational changes under new private equity management, while customers could see shifts in product development or market strategy as the new owners optimize for profitability. In the competitive medical technology sector, this move could allow Hologic to pursue long-term strategic initiatives without quarterly public market pressures, potentially enhancing its competitive position against rivals in diagnostics and women's health.

Risk Assessment

Risk Level: medium — The primary risk stems from the proposed merger, specifically the possibility that Hologic stockholders may not approve the Merger, or that the parties may not satisfy the conditions in a timely manner or at all. Additionally, the non-tradable CVR of up to $3.00 per share introduces uncertainty, as holders may receive less-than-anticipated payments, impacting the total consideration from the $79.00 per share potential. These factors introduce execution risk to the announced deal.

Analyst Insight

Investors should evaluate the $76.00 cash per share plus the potential $3.00 CVR against their investment thesis and current market price. Given the definitive agreement, consider selling shares to lock in the announced acquisition price, as further significant upside is capped by the deal terms. Monitor the CVR's potential value closely.

Revenue Breakdown

Key Numbers

• $76.00 — Cash per share (Base acquisition price for Hologic shares)
• $3.00 — Contingent Value Right (CVR) (Potential additional cash per share, non-tradable)
• $79.00 — Total potential consideration (Maximum per-share value for Hologic stockholders in the acquisition)
• $13.57B — Market Value (non-affiliate) (Aggregate market value of non-affiliate common stock as of March 29, 2025)
• 222.9M — Shares Outstanding (Total common stock shares outstanding as of November 13, 2025)

Key Players & Entities

• HOLOGIC INC (company) — Registrant and target of acquisition
• Blackstone Inc. (company) — Acquirer of Hologic
• TPG Capital (company) — Acquirer of Hologic
• $76.00 (dollar_amount) — Cash per share in acquisition
• $3.00 (dollar_amount) — Maximum contingent value right per share
• $79.00 (dollar_amount) — Total potential consideration per share
• $13,566,017,923 (dollar_amount) — Aggregate market value of non-affiliate common stock as of March 29, 2025
• 222,905,228 (dollar_amount) — Shares of common stock outstanding as of November 13, 2025
• September 27, 2025 (date) — Fiscal year end
• October 21, 2025 (date) — Date of definitive merger agreement

FAQ

Risk Factors

• Product Development and Commercialization [medium — operational]: Hologic's success depends on its ability to develop and commercialize new products and enhance existing ones. Failure to innovate or adapt to evolving market needs could lead to reduced competitiveness and financial performance.
• Regulatory Approvals and Compliance [high — regulatory]: The company operates in a highly regulated industry, requiring extensive approvals from bodies like the FDA and international equivalents. Delays or failures in obtaining approvals, or non-compliance with regulations, can significantly impact product launches and market access.
• Competition and Market Acceptance [medium — market]: Hologic faces intense competition from established players and emerging companies in its segments. Market acceptance of new technologies and products is crucial, and failure to gain traction could hinder revenue growth.
• Acquisition and Integration Risks [high — financial]: The pending acquisition by Blackstone and TPG Capital introduces risks related to integration, potential changes in strategy, and the impact of private equity ownership on operations and employee morale. The success of the acquisition and subsequent integration is critical.
• Supply Chain and Manufacturing [medium — operational]: Disruptions in the supply chain or manufacturing processes, whether due to geopolitical events, natural disasters, or other factors, could impact Hologic's ability to produce and deliver its products, leading to revenue loss and increased costs.
• Intellectual Property and Litigation [low — legal]: Protection of intellectual property is vital. Hologic may face infringement claims or litigation related to its products, which could result in significant legal costs and potential damages.
• Healthcare Reimbursement Policies [medium — market]: Changes in healthcare reimbursement policies by governments and private payers can affect the demand for Hologic's products. Unfavorable changes could reduce the affordability and adoption of its diagnostic and surgical solutions.
• Cybersecurity and Data Privacy [medium — operational]: As a technology-driven company handling sensitive health data, Hologic is exposed to cybersecurity threats. Breaches could lead to data loss, reputational damage, and regulatory penalties.

Industry Context

Hologic operates in the highly competitive medical technology sector, focusing on women's health and well-being. Key areas include diagnostics (molecular, cytology), medical imaging (mammography), and surgical products. The industry is characterized by rapid technological advancements, stringent regulatory oversight, and a growing emphasis on early disease detection and minimally invasive treatments. Consolidation through M&A is common, driven by the need for scale, R&D investment, and market access.

Regulatory Implications

Hologic's business is heavily influenced by regulatory bodies such as the FDA. Obtaining and maintaining approvals for diagnostic assays, imaging systems, and surgical devices is critical. Changes in regulatory requirements, post-market surveillance, and compliance standards can impact product development timelines, market entry, and ongoing sales. The acquisition by private equity may also lead to shifts in regulatory compliance strategies.

What Investors Should Do

1. Monitor CVR Payout Conditions
2. Evaluate Segment Performance Post-Acquisition
3. Assess Impact of Skeletal Health Product Discontinuation
4. Understand Private Equity Ownership Strategy

Key Dates

• 2025-10-21: Definitive agreement to be acquired by Blackstone Inc. and TPG Capital — Marks a significant strategic shift for Hologic, moving from public to private ownership, with a base cash price of $76.00 per share plus a potential CVR of up to $3.00.
• 2025-03-29: Aggregate market value of non-affiliate common stock reported — Provided a valuation benchmark of $13.57 billion for the company's publicly traded shares prior to the acquisition announcement.
• 2025-11-13: Shares outstanding reported — Indicated 222.9 million shares outstanding, a key figure for calculating per-share values in the acquisition.
• 2026: Planned discontinuation of Fluoroscan Insight FD systems — Indicates a strategic shift within the Skeletal Health segment, potentially impacting future revenue streams from this product line.

Glossary

Contingent Value Right (CVR)

A contractual right that provides the holder with the potential for additional payment based on the achievement of specific future milestones or events. In this case, it's up to $3.00 per share. (Represents a component of the total acquisition consideration, offering potential upside to Hologic shareholders beyond the base cash price.)

Molecular Diagnostic Assays

Tests that detect specific genetic material (DNA or RNA) to diagnose diseases or identify pathogens. Examples include Aptima assays for STDs and respiratory infections. (A core product category for Hologic's Diagnostics segment, driving significant revenue and innovation.)

Cytology Systems

Systems used to examine cells for abnormalities, often for cancer screening. Hologic's ThinPrep and Genius Digital Diagnostics systems fall into this category. (Important products within the Diagnostics segment, particularly for cervical cancer screening.)

3D Digital Mammography

An advanced form of mammography that provides multiple X-ray images of breast tissue from different angles, creating a 3D reconstruction for improved cancer detection. (A key product in Hologic's Breast Health segment, crucial for early detection of breast cancer.)

GYN Surgical Products

Medical devices used in gynecological procedures. Hologic offers systems like MyoSure and NovaSure for treatments related to women's reproductive health. (Represents a significant segment focused on therapeutic interventions in women's health.)

DXA (Dual-energy X-ray Absorptiometry)

A medical imaging technique used to measure bone mineral density, primarily for diagnosing osteoporosis. Hologic's Horizon DXA is an example. (The primary product in the Skeletal Health segment, focused on bone density assessment.)

Panther and Panther Fusion Systems

Automated molecular diagnostic instrumentation platforms developed by Hologic that run various diagnostic assays. (The core instrumentation for Hologic's molecular diagnostics business, enabling high-throughput testing.)

Non-tradable CVR

A Contingent Value Right that cannot be bought or sold on a public exchange, meaning its value is realized only if the specified conditions are met and paid out by the acquirer. (Highlights that the potential additional $3.00 per share is not liquid and depends entirely on future events and the acquirer's assessment.)

Year-Over-Year Comparison

Information comparing key metrics to the previous year, such as revenue growth, margin changes, and new risks, is not available within the provided text excerpt of the 10-K. The text focuses on the business overview, risk factors, and the acquisition agreement, without comparative financial data from prior periods.

Key Financial Figures

• $0.01 — ange on which Registered Common Stock, $0.01 par value HOLX The Nasdaq Global Select
• $76.00 — uire all outstanding Hologic shares for $76.00 per share in cash, without interest, pl
• $3.00 — nt value right ("CVR") to receive up to $3.00 per share in cash, for total potential
• $79.00 — h, for total potential consideration of $79.00 per share in cash. The non-tradable CVR

Filing Documents

• holx-20250927.htm (10-K) — 3150KB
• ex1040-thirdamendmenttosma.htm (EX-10.4) — 10KB
• ex1064-manchesterleaserev1.htm (EX-10.64) — 445KB
• CreditAgreementex1069.htm (EX-10.69) — 3031KB
• ex211-subsidiariesofhologi.htm (EX-21.1) — 56KB
• holxq4-2025ex231.htm (EX-23.1) — 5KB
• holxq4-2025ex311.htm (EX-31.1) — 9KB
• holxq4-2025ex312.htm (EX-31.2) — 9KB
• holxq4-2025ex321.htm (EX-32.1) — 5KB
• holxq4-2025ex322.htm (EX-32.2) — 5KB
• holx-20250927_g1.jpg (GRAPHIC) — 53KB
• 0000859737-25-000072.txt ( ) — 21806KB
• holx-20250927.xsd (EX-101.SCH) — 106KB
• holx-20250927_cal.xml (EX-101.CAL) — 151KB
• holx-20250927_def.xml (EX-101.DEF) — 567KB
• holx-20250927_lab.xml (EX-101.LAB) — 1238KB
• holx-20250927_pre.xml (EX-101.PRE) — 936KB
• holx-20250927_htm.xml (XML) — 3470KB

Risk Factors

Item 1A. Risk Factors 18

Unresolved Staff Comments

Item 1B. Unresolved Staff Comments 32 Item 1C. Cybersecurity 33

Properties

Item 2. Properties 34

Legal Proceedings

Item 3. Legal Proceedings 34

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 34 PART II

Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 35

Reserved

Item 6. Reserved 36

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations 37

Quantitative and Qualitative Disclosures About Market Risk

Item 7A. Quantitative and Qualitative Disclosures About Market Risk 52

Financial Statements and Supplementary Data

Item 8. Financial Statements and Supplementary Data 53

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 53

Controls and Procedures

Item 9A. Controls and Procedures 53

Other Information

Item 9B. Other Information 56 Item 9C Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 56 PART III

Directors, Executive Officers and Corporate Governance

Item 10. Directors, Executive Officers and Corporate Governance 57

Executive Compensation

Item 11. Executive Compensation 57

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 57

Certain Relationships and Related Transactions, and Director Independence

Item 13. Certain Relationships and Related Transactions, and Director Independence 57

Principal Accounting Fees and Services

Item 14. Principal Accounting Fees and Services 58 PART IV

Exhibits and Financial Statement Schedules

Item 15. Exhibits and Financial Statement Schedules 59

Form 10-K Summary

Item 16. Form 10-K Summary 65 2 Table of Contents SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS Some of the statements contained in this report and documents incorporated by reference herein are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). These statements involve known and unknown risks, uncertainties and other factors which may cause our or our industry's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements including, but not limited to: the timing, receipt and terms and conditions of any required governmental and regulatory approvals of the proposed merger (the "Merger") pursuant to the definitive agreement we entered into to be acquired by funds managed by Blackstone Inc. and TPG Capital, that could delay the consummation of the Merger or cause the parties to abandon the Merger; the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement entered into in connection with the Merger; the possibility that our stockholders may not approve the Merger; the risk that the parties to the merger agreement may not be able to satisfy the conditions to the Merger in a timely manner or at all; risks related to disruption of management time from ongoing business operations due to the Merger; the risk that any announcements relating to the Merger could have adverse effects on the market price of our common stock; the risk of any unexpected costs or expenses resulting from the Merger; the risk of any litigation relating to the Merger; the risk that the Merger and its announcement could have an adverse effect on our ability to retain and hire key personnel and to maintain relationships with customers, vendo

Business

Item 1. Business Overview We are a developer, manufacturer and supplier of premium diagnostics products, medical imaging systems, and surgical products focused on women's health and well-being through early detection and treatment. We sell and service our products through a combination of direct sales and service personnel and a network of independent distributors and sales representatives. We operate in four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. Through our Diagnostics segment, we offer a wide range of diagnostic products, which are used primarily to aid in the screening and diagnosis of human diseases. Our primary Diagnostics products include our molecular diagnostic assays, which run on our advanced instrumentation systems (Panther and Panther Fusion), our cytology systems, including the ThinPrep System, and the Genius Digital Diagnostics System, and the Rapid fFN Test. Our Aptima family of molecular diagnostic assays is used to detect, among other things, the infectious microorganisms that cause common sexually transmitted diseases, or STDs, such as chlamydia and gonorrhea, or CT/NG; certain high-risk strains of human papillomavirus, or HPV; Trichomonas vaginalis , the parasite that causes trichomoniasis; Mycoplasma genitalium; and Herpes Simplex viruses 1 and 2. We also offer viral load tests for the quantitation of Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, or HIV-1, and human cytomegalo virus, or CMV, for use on our Panther instrument system. In addition, we offer bacterial vaginosis and candida vaginitis assays, or BV/CV, for the diagnosis of vaginitis, a common and complex ailment affecting millions of women a year. Our assay portfolio also includes diagnostic tests for a range of acute respiratory infections, including SARS-CoV-2, various strains of influenza and parainfluenza, and respiratory syncytial virus, as well as a test for the detection of Group B Streptococcus, or GBS, as well as two a

View Full Filing

View this 10-K filing on SEC EDGAR